Date: 2015-05-12
Type of information: Private placement
Company: Affimed (Germany)
Investors:
Amount: $37.1 million
Funding type: private placement
Planned used:
Others: * On May 12, 2015, Affimed, a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, * On May 6, 2015, Affimed announced public offering of 5,000,000 of its common shares at a public offering price of $7.15 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the public offering are expected to be approximately $32.1 million. The offering is expected to close on or about May 12, 2015, subject to customary closing conditions. * On May 4, 2015, Affimed announced that it filed a registration statement on Form F-1/A with the Securities and Exchange Commission. The company intends to raise $35 million in this proposed public offering and may sell up to $5.25 million of additional common shares to the underwriters. Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers, and Oppenheimer & Co. Inc. is acting as lead manager. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomeseffective.
announced the closing of its previously announced public offering of 5,750,000 of its common shares at a public offering price of $7.15 per common share. The total includes 750,000 common shares issued pursuant to the underwriters’ option to purchase additional
shares, which was exercised on May 7, 2015. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the public offering are expected to be approximately $37.1 million.
Therapeutic area: Cancer - Oncology
